Business Wire

TMD-SECURITY

Share
TMD Security Launches Global Consultancy Program with Deloitte to help ATM Deployers Discover Operational Cost Savings and Benefits From Key-less ATM & Branch Access Management

TMD Security announced today the launch of a global program with consulting firm Deloitte to help banks and ATM deployers understand the annual operational cost savings and benefits from replacing physical keys and manual processes with a key-less ATM and Branch Access Management solution. Ten Deloitte customer engagements are planned in EMEA, APAC and the Americas and there is availability for a further ten free custom business case engagements before the end of the year.

“Reducing ATM operational costs has never been more critical than it is today,’’ said Cees Heuker of Hoek, CEO and Founder, TMD Security. “We are proud to announce this global relationship with Deloitte. A custom business case gives valuable insight into an ATM deployer’s specific cost savings and business benefits potential, depending on their ATM network and current access processes. Our clients discover that replacing keys and manual processes with our Access Management solution results in staggering productivity improvements and annual operational cost savings. Also, faced with the health risks associated with the COVID-19 pandemic, removing the need for keys, reducing the number of ‘meet and greets’ with key-holders at service visits, and eliminating the reliance on call centres for providing security codes brings significant safety benefits. Despite the pandemic, we can continue with the Deloitte program because interviews and data gathering can be done remotely. Interest has been strong and we are inviting ATM deployers to reserve one of the remaining slots soon.’’

TMD ATM and Branch Access Management is a key-less, centrally managed secure access solution for all types of ATMs and door locks which remotely validates the IDs of the pre-authorised user, lock and mobile device and checks the pre-approved schedule in a split second at the time of access. Randomly generated, encrypted One-Time-Codes are sent directly to the lock, with a real-time audit trail. TMD’s new Intelligent Alarm Switch integrates pre-authorised activation and deactivation of alarms in the ATM, secure room or branch into the access management solution via TMD’s One Touch Access TM Security mobile app which saves time, reduces false alerts and improves security.

“Our clients recognise that TMD Security is in a unique position to deliver proven and certified security hardware combined with intelligent software because of our sister company TMS ATM Software," added Cees. “This powerful combination of hardware and software means that we are fast to market with innovative, user-friendly access management solutions that can be tailored to our clients’ needs.’’

TMD Security will present real-world facts and figures from ATM deployers who are already reaping the benefits of key-less Access Management in a live webinar hosted by ATM Marketplace.

Company profile

TMD Security is the global leader in ATM security and ATM and Branch Access Management with headquarters in Europe and sales and support in the Americas, EMEA and APAC.

www.tmdsecurity.com ;

email: accessmanagement@tmdsecurity.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye